ORTEXORTEX News
Tracking MRCY? Get live short interest, options flow, and signals on ORTEX.Sign up free →
MR
Trader NoteMRCY

Mercury Systems Shorts Hit a Year High Before November Earnings

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 4 min readdata as of 28 Oct 2026, 18:34

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

MRCY enters its November 3 earnings report with short interest at its highest level in over a year, yet the stock has outrun nearly every peer this week, a tension worth unpacking before the print.

Short interest climbed 8.3% over the past week to 9.1% of the free float, the largest positioning the ORTEX data captures across the trailing twelve months. The move was concentrated: most of the build happened between October 22 and October 27, when shares climbed from the mid-$70s to close at $78.55. Shorts are not retreating in the face of price strength; they are adding into it. The FINRA fortnightly settlement pegged the count at 5.56 million shares as of October 15, and the daily estimate has since climbed above that level. The ORTEX short score rose to 58.3 on October 27, up from 55.8 five sessions earlier, its sharpest move in weeks. Days-to-cover stands at 12.5 on the official count, a figure that would make any rapid covering a drawn-out process.

The borrow market, however, does not support a squeeze thesis. Availability is running at roughly 798% of short interest, meaning lenders hold nearly eight times the shares already borrowed, well above the 52-week low of 443%. Cost to borrow has edged up 18% on the week to 0.55%, but that remains a trivially low absolute rate. New shorts face no friction opening positions. Options pricing tells a similar story: the put/call ratio is 0.47, just below its 20-day average of 0.44, with a z-score under 1. That is a mildly call-heavy book, not the kind of defensive hedging typically seen when a large institutional holder fears a hard downside event.

The analyst picture is broadly constructive, though the most recent data point cuts the other way. Piper Sandler on October 23 maintained an Overweight rating but cut its target sharply from $131 to $107, citing what the firm characterised as a more cautious near-term outlook. Oppenheimer initiated with Outperform and a $90 target the day before. The mean analyst target across the Street sits at $110, implying roughly 40% upside to the current price. Bull-side consensus rests on a completed turnaround: FY26 revenue of $984 million, adjusted EBITDA of $150 million, bookings up 50% to $1.5 billion, and a record backlog of $1.9 billion with unusually high forward revenue coverage of around 90% versus a historical 60%. Bears point to customer concentration (RTX, LMT, and NOC combined for 36% of FY26 revenue), continuing GAAP losses, and a $15.3 million asset impairment charge, arguing that margin recovery requires flawless execution on fixed-price development contracts. JANA Partners filed a 13D/A in March reporting a stake of 6.9%, trimmed from 8.3% at a prior filing. JANA has been on the register since August 2025 and has filed three times; its direction of travel is toward the 5% exit threshold, though per SEC disclosure rules, a holder dropping below 5% may not file again, so the current position should be treated as a lower bound. BlackRock holds 15.6% of shares per its most recent filing.

Insider activity over the past 90 days points firmly in one direction. CEO William Ballhaus sold just over $13.6 million of stock in open-market transactions on August 25 and 26, with no 10b5-1 plan attached, the largest insider print in the recent window. EVP and CHRO Steven Ratner sold $338,000 on September 3, also outside a plan. The CLO Stuart Kupinsky has sold 1,000 shares twice, in September and October, both under a 10b5-1 programme. The 90-day net across all insiders is a sale of 452,000 shares worth approximately $41.9 million. The CEO sales in particular, discretionary rather than pre-arranged, carry more weight than the planned transactions.

On a week-over-week basis, MRCY's 5.4% gain stands out against its closest peers. AVAV rose 7.7% and RCAT jumped 7.7%, matching the move. But DCO slipped 1% and MOG.A fell 3%. LOAR and CW gave back ground too. Mercury's gain is not a sector-wide tailwind; it is specific to the name, and it arrived while shorts were adding to positions.

The past two earnings events both generated sharp moves. The August 18 print produced a 10.7% one-day decline and a 22.6% five-day loss. The May print delivered a small positive day but a 3.4% five-day loss. The average first-day move across those two events is a decline. The short interest build, the insider selling, and the Piper Sandler target cut all arrived in the week before a November 3 result. The specific thing to watch is whether the Q1 fiscal 2027 bookings print sustains or challenges the $1.9 billion backlog record the bull case rests on.

Stocks in this article

See the live data behind this article on ORTEX.

Open MRCY on ORTEX →

How this article was generated

Generated
28 Oct 2026, 18:35
Data as of
28 Oct 2026, 18:34
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.